Mount Yale Investment Advisors’s Amicus Therapeutics FOLD Stock Holding History

Mount Yale Investment Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-367,179	Closed	-$5.31M	–	1222
2026 Q1	$5.31M	Sell	367,179 -378	-0.1%	-$5.42K	0.12%	176
2025 Q4	$5.23M	Sell	367,557 -8,163	-2%	-$80.2K	0.25%	81
2025 Q3	$2.96M	Buy	+375,720	New	+$2.67M	0.21%	112
2024 Q3	–	Sell	-11,431	Closed	-$113K	–	568
2024 Q2	$113K	Sell	11,431 -17	-0.1%	-$175	0.01%	527
2024 Q1	$135K	Buy	11,448 +304	+3%	+$3.89K	0.01%	523
2023 Q4	$158K	Buy	11,144 +61	+0.6%	+$693	0.02%	480
2023 Q3	$135K	Buy	+11,083	New	+$143K	0.01%	486

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Mount Yale Investment Advisors's FOLD Position: Q2 2026 in Review

Mount Yale Investment Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 367,179 shares — an estimated $5.31M sold.

Mount Yale Investment Advisors first reported a position in FOLD in Q3 2023 and held it in 7 quarters. The position peaked at $5.31M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Mount Yale Investment Advisors reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Mount Yale Investment Advisors sold 367,179 Amicus Therapeutics shares in Q2 2026, an estimated $5.31M.
Mount Yale Investment Advisors first reported a position in Amicus Therapeutics in Q3 2023 and held it in 7 quarters.
Mount Yale Investment Advisors's Amicus Therapeutics position peaked at $5.31M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.